Cimetidine
Cimetidine, sold under the brand name Tagamet among others, is a histamine H2 receptor antagonist that inhibits stomach acid production. It is mainly used in the treatment of heartburn and peptic ulcers.
Clinical data | |
---|---|
Pronunciation | /sɪˈmɛtɪdiːn/ or /saɪˈmɛtɪdiːn/ |
Trade names | Tagamet, others |
Other names | SKF-92334 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682256 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth, intramuscular injection, intravenous infusion |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 60–70% |
Protein binding | 13–25% |
Metabolism | Liver |
Metabolites | • Cimetidine sulfoxide • Hydroxycimetidine • Guanyl urea cimetidine |
Onset of action | 30 minutes |
Elimination half-life | 123 minutes (~2 hours) |
Duration of action | 4–8 hours |
Excretion | Urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.052.012 |
Chemical and physical data | |
Formula | C10H16N6S |
Molar mass | 252.34 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
With the development of proton pump inhibitors, such as omeprazole, approved for the same indications, cimetidine is available as an over-the-counter formulation to prevent heartburn or acid indigestion, along with the other H2-receptor antagonists.
Cimetidine was developed in 1971 and came into commercial use in 1977. Cimetidine was approved in the United Kingdom in 1976, and was approved in the United States by the Food and Drug Administration in 1979.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.